![Elena Ridloff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elena Ridloff
Direttore Finanziario/CFO presso
SIONNA THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 30/06/2026
Profilo
La signora Elena H. Ridloff, CFA, è un amministratore indipendente di Kymera Therapeutics, Inc., un amministratore indipendente di Kronos Bio, Inc. e un Chief Financial Officer & Executive Vice President di ACADIA Pharmaceuticals, Inc. Fa parte del Consiglio di amministrazione di Kymera Therapeutics, Inc. e Kronos Bio, Inc. La signora Ridloff è stata in precedenza impiegata come vicepresidente delle relazioni con gli investitori presso Alexion Pharmaceuticals, Inc., amministratore delegato e socio dirigente presso BioVision, Inc., analista senior presso Maverick Capital Ltd. e analista senior presso Paramount BioCapital Asset Management, Inc. Si è laureata presso l'Università della Pennsylvania.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/04/2026 | 38.532 ( 0,09% ) | 2 M $ | 30/06/2026 |
Posizioni attive di Elena Ridloff
| Società | Posizione | Inizio |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 12/03/2021 |
| SIONNA THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/01/2021 |
Precedenti posizioni note di Elena Ridloff
| Società | Posizione | Fine |
|---|---|---|
| KRONOS BIO, INC. | Direttore/Membro del Consiglio | 20/06/2025 |
| ACADIA PHARMACEUTICALS INC. | Direttore Finanziario/CFO | 10/09/2021 |
| ALEXION PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | 01/03/2018 |
BioVision, Inc.
 BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Amministratore Delegato | 01/04/2014 |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Analyst-Equity | 01/01/2012 |
Formazione di Elena Ridloff
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
93
Relazioni di 1° grado
10
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 10 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Paramount BioCapital Asset Management manages hedge funds and private equity funds that focus on investments in healthcare and life sciences companies. The firm invests globally, with emphasis on the stocks of small-cap healthcare technology companies. | Finance |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Finance |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Stealth BioTherapeutics, Inc.
 Stealth BioTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat the mitochondrial dysfunctions and age-related diseases | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
